NAS:IFRX (Germany) Also trade in: Germany

InflaRx NV

$ 2.89 0 (0%)
Volume: 790,131 Avg Vol (1m): 1,751,866
Market Cap $: 75.04 Mil Enterprise Value $: -95,410,000.00
P/E (TTM): 0.00 P/B: 0.44
Earnings Power Value 0
Net Current Asset Value 6.27
Tangible Book 6.34
Projected FCF 0
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
N/A
Altman Z-Score 4.52
DISTRESS
GREY
SAFE

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
ROE % -19.76
ROE range over the past 10 years
Min: -50.22, Med: -50.22, Max: -19.76
Current: -19.76
-50.22
-19.76
ROA % -18.96
ROA range over the past 10 years
Min: -137.12, Med: -53.82, Max: -18.96
Current: -18.96
-137.12
-18.96
ROC (Joel Greenblatt) % -4500.02
ROC (Joel Greenblatt) range over the past 10 years
Min: -14958.92, Med: -5660.16, Max: -3542.2
Current: -4500.02
-14958.92
-3542.2
3-Year Total EBITDA Growth Rate -129.40
N/A

» IFRX's 30-Y Financials

Financials (Next Earnings Date: 2019-08-09)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:IFRX

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare ROCO:4162 NAS:ADRO NAS:ECYT NAS:CBAY XPAR:STAGR NAS:CERS XAMS:PHARM NAS:URGN XKRX:199800 NAS:CCXI NAS:DCPH OSTO:RECI B NAS:NVAX HKSE:00775 SZSE:300381 NAS:ANIP NAS:ANIK NAS:QURE NAS:OMER TSE:3034
Traded in other countries IF0.Germany
Address Winzerlaer Strasse 2, Jena, DEU, 07745
InflaRx NV is a clinical-stage biopharmaceutical company is focused on applying proprietary anti-C5a technology to discover and develop specific inhibitors of the complement activation factor known as C5a. The lead product candidate of the company is IFX-1, which is developed for the treatment of Hidradenitis Suppurativa, a rare and chronic debilitating systemic inflammatory skin disease. The company's proprietary anti-C5a technology is an inflammatory mediator involved in the progression of a variety of autoimmune and other inflammatory diseases. It is also developing IFX-1 for the treatment of AAV, a life-threatening autoimmune disease associated with powerful inflammatory flares that impair kidney function and lead to fatal organ dysfunction.

Ratios

Current vs industry vs history
PB Ratio 0.44
PB Ratio range over the past 10 years
Min: 0, Med: 0, Max: 8
Current: 0.44
0
8
EV-to-EBIT 2.71
EV-to-EBIT range over the past 10 years
Min: -56.19, Med: 0, Max: 2.74
Current: 2.71
-56.19
2.74
EV-to-EBITDA 2.81
EV-to-EBITDA range over the past 10 years
Min: -56.43, Med: 0, Max: 2.82
Current: 2.81
-56.43
2.82
Current Ratio 18.08
Current Ratio range over the past 10 years
Min: 7.96, Med: 18.38, Max: 43.98
Current: 18.08
7.96
43.98
Quick Ratio 18.08
Quick Ratio range over the past 10 years
Min: 7.96, Med: 18.38, Max: 43.98
Current: 18.08
7.96
43.98

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -2.30
N/A

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 0.46
Price-to-Tangible-Book range over the past 10 years
Min: 0.45, Med: 4.89, Max: 5.96
Current: 0.46
0.45
5.96
Earnings Yield (Joel Greenblatt) % 36.36
Earnings Yield (Greenblatt) range over the past 10 years
Min: -8.9, Med: 0, Max: 80.9
Current: 36.36
-8.9
80.9

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 0
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA N
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N